Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

MNPR Monopar Therapeutics

Post-Mkt 04-30 18:45:17 EDT

52.15

+2.03

+4.05%

盘后52.15

+0.000.00%

16:10 EDT

High53.63	Low50.26	Vol81.23K
Open50.26	D1 Closing50.12	Amplitude6.72%
Mkt Cap348.50M	Tradable Cap257.18M	Total Shares6.68M
T/O4.27M	T/O Rate1.65%	Tradable Shares4.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"MNPR","market":"US","secType":"STK","nameCN":"Monopar Therapeutics","latestPrice":52.15,"timestamp":1777579200000,"preClose":50.12,"halted":0,"volume":81232,"hourTrading":{"tag":"盘后","latestPrice":52.15,"preClose":52.15,"latestTime":"16:10 EDT","volume":3869,"amount":201768.35,"timestamp":1777579804081,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04050279329608941,"floatShares":4931541,"shares":6682584,"eps":-1.850852,"marketStatus":"Post-Mkt","change":2.03,"latestTime":"04-30 18:45:17 EDT","open":50.26,"high":53.63,"low":50.26,"amount":4267518.5095,"amplitude":0.067239,"askPrice":84.41,"askSize":200,"bidPrice":51.95,"bidSize":115,"shortable":3,"etf":0,"ttmEps":-1.850852,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1777593600000},"marketStatusCode":4,"adr":0,"listingDate":1576731600000,"exchange":"NASDAQ","adjPreClose":50.12,"postHourTrading":{"tag":"盘后","latestPrice":52.15,"preClose":52.15,"latestTime":"16:10 EDT","volume":3869,"amount":201768.35,"timestamp":1777579804081,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.634494},"requestUrl":"/m/hq/s/MNPR","defaultTab":"news","newsList":[{"id":"2632665904","title":"Monopar Therapeutics announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2632665904","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632665904?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:05","pubTimestamp":1777579558,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics will hold its annual stockholders meeting in Wilmette, Illinois on June 22, 2026.Shareholders will vote on election of six directors, including director nominee Nicole Sweeny.Advisory vote on named executive officer compensation is scheduled for consideration.Ballot also includes approval of Monopar 2026 Stock Incentive Plan, which would add 600,000 new shares to equity plan capacity.Meeting agenda includes ratification of BPM LLP as independent registered public accounting firm for 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDL3H0KSs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629603200","title":"Analysts Offer Insights on Healthcare Companies: Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (CLPT) and CG Oncology, Inc. (CGON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629603200","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629603200?lang=en_us&edition=fundamental","pubTime":"2026-04-21 21:40","pubTimestamp":1776778846,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Monopar Therapeutics Inc (MNPR), ClearPoint Neuro (C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monopar-therapeutics-inc-mnpr-clearpoint-neuro-clpt-and-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-monopar-therapeutics-inc-mnpr-clearpoint-neuro-clpt-and-cg-oncology-inc-cgon-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","CGON","XLV","BK4137","LABU","HCSG","CG","BK4082","BK4135","BK4585","IE00BGHQF748.EUR","BK4588","BK4581","XBI","CLPT","LU0029874061.USD","BK4139","MNPR","IE00B3QW5Z07.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629603809","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629603809","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629603809?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:00","pubTimestamp":1776769222,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Whitehawk Therapeutics (WHWK), COMPASS Pathways (CMPS) and Monopa...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-whitehawk-therapeutics-whwk-compass-pathways-cmps-and-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-whitehawk-therapeutics-whwk-compass-pathways-cmps-and-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR","XLV","BK4588","LU0029874061.USD","BK4581","BK4139","LABU","CMPS","LU0128526141.USD","BK4585","XBI","WHWK","BK4137","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628792282","title":"Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840","url":"https://stock-news.laohu8.com/highlight/detail?id=2628792282","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628792282?lang=en_us&edition=fundamental","pubTime":"2026-04-20 08:50","pubTimestamp":1776646245,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (MNPR) announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 showing greater neurologic benefi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monopar-announces-new-analyses-from-phase-3-focus-trial-of-alxn1840-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monopar-announces-new-analyses-from-phase-3-focus-trial-of-alxn1840-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628579182","title":"Monopar says Phase 3 trial shows ALXN1840 beats standard care in neurologic Wilson disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2628579182","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628579182?lang=en_us&edition=fundamental","pubTime":"2026-04-20 07:00","pubTimestamp":1776639620,"startTime":"0","endTime":"0","summary":"Monopar reported new Phase 3 FoCus trial analyses showing ALXN1840 delivered greater neurologic benefit than standard of care in Wilson disease patients with neurologic symptoms at baseline.Results were presented at American Academy of Neurology Annual Meeting 2026 in a late-breaker oral and poster session.Data showed more patients improved and fewer worsened on ALXN1840 versus standard of care through Week 48.Long-term follow-up indicated neurologic benefit increased on continued treatment and held up for about 3 years.Monopar kept plan for a mid-2026 FDA New Drug Application submission for ALXN1840.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260419:nNDL4Ng4pB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4585","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD","IE00BN0W2W23.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","BK4112","SG9999014039.USD","BK4588","LU2210149790.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","LU2210150020.SGD","BK4139","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625601082","title":"Monopar Therapeutics Inc (MNPR) Gets a Buy from JonesTrading","url":"https://stock-news.laohu8.com/highlight/detail?id=2625601082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625601082?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:37","pubTimestamp":1775507875,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $130.00. Roy c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/monopar-therapeutics-inc-mnpr-gets-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/monopar-therapeutics-inc-mnpr-gets-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623671345","title":"Monopar Therapeutics Inc (MNPR) Receives a Buy from Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2623671345","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623671345?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:37","pubTimestamp":1774877839,"startTime":"0","endTime":"0","summary":"In a report released today, Chad Messer from Lake Street maintained a Buy rating on Monopar Therapeutics Inc, with a price target of $103.00. Accor...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/monopar-therapeutics-inc-mnpr-receives-a-buy-from-lake-street-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/monopar-therapeutics-inc-mnpr-receives-a-buy-from-lake-street-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623343770","title":"Monopar Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2623343770","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623343770?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:31","pubTimestamp":1774877472,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryMonopar Therapeutics Inc MNPR.OQ reported a quarterly adjusted loss of 64 cents per share for the quarter e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nL8N40I13X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623231793","title":"Monopar Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2623231793","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623231793?lang=en_us&edition=fundamental","pubTime":"2026-03-30 20:10","pubTimestamp":1774872600,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 30, 2026 08:10 ET (12:10 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622046871","title":"Monopar Therapeutics Q4 net loss narrows on lower R&D costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2622046871","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622046871?lang=en_us&edition=fundamental","pubTime":"2026-03-28 01:18","pubTimestamp":1774631916,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Q4 net loss narrows on lower R&D costsOverviewUS biopharmaceutical firm's Q4 net loss narrowed yr/yrLower R&D expenses reflect absence of one-time ALXN1840 in-licensing costs incu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL1N40F0RW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622871481","title":"Monopar Therapeutics Q4 EPS $(0.61) Misses $(0.54) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2622871481","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622871481?lang=en_us&edition=fundamental","pubTime":"2026-03-28 01:06","pubTimestamp":1774631173,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 72.65 percent increase over losses of $(2.23) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51517102/monopar-therapeutics-q4-eps-0-61-misses-0-54-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622653871","title":"Monopar Therapeutics FY2025 net loss narrows 12% to $(13.7) million; interest income jumps more than 6x to $3.0 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622653871","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622653871?lang=en_us&edition=fundamental","pubTime":"2026-03-28 01:01","pubTimestamp":1774630902,"startTime":"0","endTime":"0","summary":"Monopar published its annual report on Form 10-K, reporting a net loss of USD 13.7 million and an operating loss of USD 16.7 million.General and administrative expense rose more than doubled to USD 6.8 million, primarily reflecting higher board and personnel compensation and increased patent legal and other costs.Interest income increased more than doubled to USD 3.0 million, attributed to interest earned on U.S. Treasury securities and commercial paper and higher bank balances following the September 2025 capital raise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL7dNprS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622871618","title":"Monopar Therapeutics Q4 Net Income USD -5.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2622871618","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622871618?lang=en_us&edition=fundamental","pubTime":"2026-03-28 01:00","pubTimestamp":1774630800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nPLX28CFA1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622958871","title":"Press Release: Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622958871","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622958871?lang=en_us&edition=fundamental","pubTime":"2026-03-28 01:00","pubTimestamp":1774630800,"startTime":"0","endTime":"0","summary":"WILMETTE, Ill., March 27, 2026  -- Monopar Therapeutics Inc.  , a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments.\"2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet and continued progress toward a planned New Drug Application submission for ALXN1840 in Wilson disease,\" said Chandler Robinson, MD, Chief Executive Officer of Monopar. \"We also recently strengthened our leadership team with the addition of Susan Rodriguez as Chief Commercial and Strategy Officer as we prepare for the potential launch of ALXN1840. We are grateful to the Wilson disease patients and their families whose experiences have informed our efforts to advance ALXN1840.\". ALXN1840 -- NDA Submission Planned for Mid-2026 for Wilson Disease. Based on","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622827589","title":"Monopar Therapeutics Inc  expected to post a loss of 49 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622827589","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622827589?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:48","pubTimestamp":1774619300,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc  expected to post a loss of49cents a share - Earnings Preview Monopar Therapeutics Inc MNPR.OQ MNPR.O is expected to  show no change in quarterly revenue when it reports  resu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F19M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617256269","title":"Monopar Therapeutics files initial beneficial ownership statement for CCSO Susan Rodriguez","url":"https://stock-news.laohu8.com/highlight/detail?id=2617256269","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617256269?lang=en_us&edition=fundamental","pubTime":"2026-03-05 06:25","pubTimestamp":1772663136,"startTime":"0","endTime":"0","summary":"Monopar Therapeutics Inc. filed an initial statement of beneficial ownership  reporting Susan Rodriguez as an officer . The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Monopar Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDL5M83F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616333249","title":"Press Release: Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2616333249","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616333249?lang=en_us&edition=fundamental","pubTime":"2026-03-02 21:00","pubTimestamp":1772456400,"startTime":"0","endTime":"0","summary":"WILMETTE, Ill., March 02, 2026  -- Monopar Therapeutics Inc.  , a clinical--stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application  to the U.S. Food and Drug Administration  in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson disease.\"Susan is a highly accomplished commercial and strategic leader with a distinguished track record of successfully launching innovative rare disease therapies and guiding organizations through high-growth phases,\" said Chandler Robinson, MD, Monopar's Chief Executive Officer. \"Her experience building strong-performing commercial teams will be invaluable as Monopar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNPR","BK4120","TISI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613784570","title":"BTIG Remains a Buy on Monopar Therapeutics Inc (MNPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613784570","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613784570?lang=en_us&edition=fundamental","pubTime":"2026-02-23 20:36","pubTimestamp":1771850201,"startTime":"0","endTime":"0","summary":"BTIG analyst Jeet Mukherjee reiterated a Buy rating on Monopar Therapeutics Inc today and set a price target of $104.00. Mukherjee covers the Healt...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/btig-remains-a-buy-on-monopar-therapeutics-inc-mnpr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNPR","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2608982861","title":"Monopar Therapeutics Price Target Maintained With a $104.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2608982861","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608982861?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:07","pubTimestamp":1770037620,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 02, 2026 08:07 ET (13:07 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607805190","title":"Monopar Therapeutics Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2607805190","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607805190?lang=en_us&edition=fundamental","pubTime":"2026-01-29 21:19","pubTimestamp":1769692740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MNPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 08:19 ET (13:19 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNPR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monopartx.com","stockEarnings":[{"period":"1week","weight":-0.0597},{"period":"1month","weight":-0.0595},{"period":"3month","weight":-0.2557},{"period":"6month","weight":-0.4183},{"period":"1year","weight":0.1945},{"period":"ytd","weight":-0.2325}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.22612},{"month":2,"riseRate":0.285714,"avgChangeRate":0.090755},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.182533},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.038183},{"month":5,"riseRate":0.166667,"avgChangeRate":-0.085228},{"month":6,"riseRate":0.666667,"avgChangeRate":0.04528},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.047687},{"month":8,"riseRate":0,"avgChangeRate":-0.159034},{"month":9,"riseRate":0.333333,"avgChangeRate":0.484161},{"month":10,"riseRate":0.5,"avgChangeRate":0.223985},{"month":11,"riseRate":0.666667,"avgChangeRate":0.047001},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.031256}],"exchange":"NASDAQ","name":"Monopar Therapeutics","nameEN":"Monopar Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monopar Therapeutics,MNPR,Monopar Therapeutics股票,Monopar Therapeutics股票老虎,Monopar Therapeutics股票老虎国际,Monopar Therapeutics行情,Monopar Therapeutics股票行情,Monopar Therapeutics股价,Monopar Therapeutics股市,Monopar Therapeutics股票价格,Monopar Therapeutics股票交易,Monopar Therapeutics股票购买,Monopar Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monopar Therapeutics(MNPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monopar Therapeutics(MNPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction